Recursion Pharmaceuticals has reported updated data from its ELUCIDATE & TUPELO trials, but the stock has failed to mount a ...

AI 制药上市公司 Recursion（NASDAQ: RXRX）宣布与英伟达（NVIDIA）建立了合作伙伴关系，并获得英伟达 5000 万美元的投资。 AI 制药上市公司 Recursion（NASDAQ: RXRX）宣布与英伟达（NVIDIA）建立了合作伙伴关系，并获得英伟达 5000 万美元的投资。 达成协议后，两家公司计划 ...

We came across a bullish thesis on Recursion Pharmaceuticals, Inc. on r/stocks by Antique-Reference585. In this article, we ...

And its investments in AI could, eventually, lead to important monetization opportunities even beyond advertising, perhaps ...

Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) is one of the best debt-free penny stocks to buy right now. On December 17, ...

Recursion Pharmaceuticals（纳斯达克股票代码：RXRX） 董事Christopher Gibson于2026年1月5日以每股4.25美元的价格出售了4万股A类普通股，总计17万美元。根据 InvestingPro 数据显示，该交易发生之际，该公司股票在过去一周内价格大幅上涨了18.83%，目前股价为4.86美元。

Recursion Pharmaceuticals (RXRX) closed at $4.65 in the latest trading session, marking a -4.12% move from the prior day.

Brings together Recursion’s scaled biology exploration and translational capabilities with Exscientia’s precision chemistry design and small molecule automated synthesis capabilities to create a ...

Shares of Recursion Pharmaceuticals are down by about 47% from a peak the stock set this February. The company uses automation and artificial intelligence to optimize the new drug-discovery process.

Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced today its CEO & President, Najat Khan, Ph.D., will present Tuesday, January 13 ...

Wondering if Recursion Pharmaceuticals at around US$4.67 a share is priced for its potential or still misunderstood by the ...

Recursion extended its winning streak to a fourth day on Wednesday, jumping 6.81 percent to close at $4.86 apiece as ...